Maryland State Retirement & Pension System Grows Holdings in Glaukos Corporation $GKOS

Maryland State Retirement & Pension System grew its stake in shares of Glaukos Corporation (NYSE:GKOS) by 4.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,793 shares of the medical instruments supplier’s stock after acquiring an additional 751 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Glaukos were worth $1,735,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of GKOS. SG Americas Securities LLC increased its stake in shares of Glaukos by 35.2% during the 1st quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier’s stock valued at $485,000 after acquiring an additional 1,283 shares during the last quarter. Handelsbanken Fonder AB increased its position in Glaukos by 25.2% during the 1st quarter. Handelsbanken Fonder AB now owns 18,400 shares of the medical instruments supplier’s stock worth $1,811,000 after purchasing an additional 3,700 shares in the last quarter. Elevation Point Wealth Partners LLC increased its position in Glaukos by 78.2% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 3,221 shares of the medical instruments supplier’s stock worth $317,000 after purchasing an additional 1,413 shares in the last quarter. Exchange Traded Concepts LLC increased its position in Glaukos by 27.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,626 shares of the medical instruments supplier’s stock worth $652,000 after purchasing an additional 1,430 shares in the last quarter. Finally, Avior Wealth Management LLC increased its position in Glaukos by 30.1% during the 1st quarter. Avior Wealth Management LLC now owns 3,384 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 782 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Glaukos in a research report on Wednesday, October 1st. They set a “buy” rating and a $103.00 target price for the company. UBS Group increased their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Mizuho set a $130.00 target price on shares of Glaukos in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $118.00.

Glaukos Stock Performance

Glaukos stock opened at $82.55 on Friday. The stock has a market cap of $4.73 billion, a P/E ratio of -50.03 and a beta of 0.76. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $87.95 and a 200-day moving average of $92.69. Glaukos Corporation has a 52 week low of $77.10 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million during the quarter, compared to analysts’ expectations of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business’s revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.